vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83 According to Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $55.83.

A number of equities analysts recently issued reports on VTVT shares. HC Wainwright reduced their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and issued a $57.00 price target on shares of vTv Therapeutics in a research note on Wednesday, October 14th. Finally, Wall Street Zen downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th.

vTv Therapeutics Stock Down 9.5%

vTv Therapeutics stock opened at $21.74 on Friday. The company’s 50-day moving average price is $29.46 and its 200-day moving average price is $33.29. vTv Therapeutics has a twelve month low of $21.72 and a twelve month high of $44.00. The company has a market cap of $85.66 million, a PE ratio of -20.51 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.15. As a group, sell-side analysts expect that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 114.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,360 shares of the biotechnology company’s stock after purchasing an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in vTv Therapeutics were worth $161,000 as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.